Active home-based cancer treatment

Journal of Multidisciplinary Healthcare

Volumn 5, Issue , 2012, Pages 137-143

  Bordonaro, Sebastiano ^a   Raiti, Fabio ^a   Di Mari, Annamaria ^a   Lopiano, Calogera ^a   Romano, Fabrizio ^a   Pumo, Vitalinda ^a   Rametta Giuliano, Sebastiano ^a   Iacono, Margherita ^a   Lanteri, Eleonora ^a   Puzzo, Elena ^a   Spada, Sebastiano ^a   Tralongo, Paolo ^a  

^a ASP 8   (Italy)

Author keywords

Cancer; Compliance; Home based; Quality of life; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; IBANDRONIC ACID; IMATINIB; NAVELBINE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CAREGIVER SUPPORT; CLINICAL ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOCTOR PATIENT RELATION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ C30 VERSION 2.0; FEMALE; HEALTH CARE ACCESS; HOME CARE; HUMAN; MALE; NURSE ATTITUDE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; VISITING NURSING SERVICE;

EID: 84874785347     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S31494     Document Type: Article

References (27)

1. Palmieri FM, Barton DL. Challenges of oral medications in patients with advanced breast cancer. Semin Oncol Nurs. 2007;23(4 Suppl 2):17-22.
2. Liu G, Franssen E, Fitch MI, etal. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
3. Tsoutsou PG, Belkacemi Y, Gligorov J, etal. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. Oncologist. 2010;15:1169-1178.
4. Demetri GD, von Mehren M, Blanke CD, etal. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
5. Welt A, von Minckwitz G, Oberhoff C, etal. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol. 2005;16:64-69.
6. Geyer CE, Forster J, Lindquist D, etal. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
7. Shepherd FA, Rodrigues Pereira J, etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132.
8. Motzer RJ, Michaelson MD, Redman BG, etal. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
9. Llovet JM, Ricci S, Mazzaferro V, etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
10. Centers for Disease Control and Prevention (CDC). Cancer survivors-United States, 2007. MMWR Morb Mortal Wkly Rep. 2011;60:269-272.
11. Xue D, Li PP. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine. Chin J Integr Med. 2011;17:228-231.
12. World Health Organization. WHO handbook for reporting results of cancer treatment. Neoplasma. 1980;20:37-46.
13. Aaronson NK, Ahmedzai S, Bergman B, etal. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
14. Oken MM, Creech RH, Tormey DC, etal. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
15. Oliveira EX, Melo EC, Pinheiro RS, etal. Access to cancer care: mapping hospital admissions and high-complexity outpatient care flows. The case of breast cancer. Cad Saude Publica. 2011;27:317-326. Portuguese.
16. Haynes RB, Taylor DW, Sackett DL. Compliance In Health Care. Baltimore, MD: The Johns Hopkins University Press; 1979.
17. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151:1842-1847.
18. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993;71(Suppl 10):3441-3449.
19. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-2571.
20. Patricia Calleja, Judit Huarte, Maite Agüeros, Luisa Ruiz-Gatón, Socorro Espuelas, Juan M Irache. Molecular buckets: cyclodextrins for oral cancer therapy. Therapeutic Delivery. 2012;3(1):43-57.
21. Liu G, Franssen E, Fitch MI, etal. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
22. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7(Suppl 6):5-9.
23. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56-66.
24. Weingart SN, Brown E, Bach PB, etal. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6 Suppl 3:1-14.
25. Hall M, Lloyd H. Evaluating patients' experience of home and hospital chemotherapy. Cancer Nurs Pract. 2008;7:23-26.
26. Sweeney L, Halpert A, Waranoff J. Patient-centered management of complex patients can reduce costs without shortening life. Am J Manag Care. 2007;13:84-92.
27. Tralongo P, Ferraù F, Borsellino N, etal. Cancer patient-centered home care: a new model for health care in oncology. Ther Clin Risk Manag. 2011;7:387-392.